GRP and gastrointestinal stromal tumor: 68Ga-NeoBOMB1, now called 68Ga-NeoB—a novel DOTA-coupled GRPR antagonist derived from native bombesin by C-terminal Leu13-Met14-NH2 modification—was identified to be a suitable candidate for GIST targeting [24] within the EU-FP7 project Closed-loop Molecular Environment for Minimally Invasive Treatment of Patients with Metastatic Gastrointestinal Stromal Tumours (‘MITIGATE’, grant agreement number 602306).